Interferon-α/β upregulate IL-15 expression in vitro and in vivo: Analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment

Cancer Immunology, Immunotherapy

Volumn 55, Issue 4, 2006, Pages 394-403

  Yamaji, Kouzaburo ^a   Nabeshima, Shigeki ^a   Murata, Masayuki ^a   Chong, Yong ^a   Furusyo, Norihiro ^a   Ikematsu, Hideyuki ^a   Hayashi, Jun ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERLEUKIN 15;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; UPREGULATION;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-15; LIVER NEOPLASMS; MALE; MIDDLE AGED; UP-REGULATION;

EID: 30444448237     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0005-x     Document Type: Article

References (53)

1. Alter HJ (1995) To C or not to C: these are the questions. Blood 85:1681-1695
2. Tong MJ, el-Farra NS, Reikes AR et al (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466
3. Tanaka K, Ikematsu H, Hirohata T et al (1996) Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 88:742-746
4. Tagger A, Donato F, Ribero ML et al (1999) Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81:695-699
5. Hayashi J, Furusyo N, Ariyama I et al (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523-1527
6. Davis GL, Balart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501-1506
7. Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510
8. Kakumu S, Arao M, Yoshioka K et al (1990) Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 85:655-659
9. Hayashi J, Ohmiya M, Kishihara Y et al (1994) A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151-2156
10. Hayashi J, Kishihara Y, Ueno K et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177-181
11. Furusyo N, Hayashi J, Ohmiya M et al (1999) Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 44:608-617
12. Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055
13. Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131:174-181
14. Kashiwagi K, Furusyo N, Kubo N et al (2003) A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 9:333-340
15. Stark GR, Kerr IM, Williams BR et al (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264
16. Meurs EF, Galabru J, Barber GN et al (1993) Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90:232-236
17. Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29:1708-1717
18. Murphy D, Detjen KM, Welzel M et al (2001) Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346-356
19. Takaoka A, Hayakawa S, Yanai H et al (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516-523
20. von Hoegen P (1995) Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 47:157-162
21. Hiroishi K, Tuting T, Lotze MT (2000) IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164:567-572
22. Biron CA, Nguyen KB, Pien GC et al (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189-220
23. Ohzato H, Monden M, Yoshizaki K et al (1993) Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun 197:1556-1562
24. Kawakami Y, Hayashi J, Ueno K et al (1997) Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. Fukuoka Igaku Zasshi 88:274-282
25. Mattei F, Schiavoni G, Belardelli F et al (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:1179-1187
26. Grabstein KH, Eisenman J, Shanebeck K et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965-968
27. Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395-1403
28. Kennedy MK, Glaccum M, Brown SN et al (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771-780
29. Sharif-Askari E, Fawaz LM, Tran P et al (2001) Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst 93:1724-1732
30. Lodolce JP, Boone DL, Chai S et al (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669-676
31. Zhang X, Sun S, Hwang I et al (1998) Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 8:591-599
32. Liu K, Catalfamo M, Li Y et al (2002) IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8 + memory T cells. Proc Natl Acad Sci USA 99:6192-6197
33. Hayashi J, Yoshimura E, Kishihara Y et al (1996) Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314-318
34. Strehlau J, Pavlakis M, Lipman M et al (1997) Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 94:695-700
35. Smith XG, Bolton EM, Ruchatz H et al (2000) Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival. J Immunol 165:3444-3450
36. Conti F, Frappier J, Dharancy S et al (2003) Interleukin-15 production during liver allograft rejection in humans. Transplantation 76:210-216
37. McInnes IB, al-Mughales J, Field M et al (1996) The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2:175-182
38. McInnes IB, Leung BP, Sturrock RD et al (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3:189-195
39. Lu J, Giuntoli RL, 2nd, Omiya R et al (2002) Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 8:3877-3884
40. Lewko WM, Smith TL, Bowman DJ et al (1995) Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother 10:13-20
41. Yajima T, Nishimura H, Ishimitsu R et al (2002) Overexpression of IL-15 in vivo increases antigen-driven memory CD8 + T cells following a microbe exposure. J Immunol 168:1198-1203
42. Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T cells. Proc Natl Acad Sci USA 101:1969-1974
43. Fehniger TA, Cooper MA, Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13:169-183
44. Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286
45. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54
46. Radaeva S, Jaruga B, Hong F et al (2002) Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122:1020-1034
47. Azimi N, Shiramizu KM, Tagaya Y et al (2000) Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol 74:7338-7348
48. Jinushi M, Takehara T, Tatsumi T et al (2003) Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 171:5423-5429
49. Damdinsuren B, Nagano H, Sakon M et al (2003) Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 10:1184-1190
50. Domanski P, Nadeau OW, Platanias LC et al (1998) Differential use of the betaL subunit of the type 1 interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J Biol Chem 273:3144-3147
51. Rani MR, Foster GR, Leung S et al (1996) Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271:22878-22884
52. Rani MR, Gauzzi C, Pellegrini S et al (1999) Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem 274:1891-1897
53. Yamaji K, Hayashi J, Kawakami Y et al (1998) Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J Clin Gastroenterol 26:193-199